XKDCT-080 by Guangdong Xiankangda Biotechnology for Colorectal Cancer: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XKDCT-080 overview
XKDCT-080 is under development for the treatment of GCC-positive recurrent or refractory solid tumor, colorectal cancer, gastric cancer, and esophageal cancer. The therapeutic candidate comprises of T cells genetically engineered to express chimeric antigen receptors targeting cells expressing guanylate cyclase C (GCC). It is administered through intravenous route.
Guangdong Xiankangda Biotechnology overview
Guangdong Xiankangda Biotechnology is a medical research based company which is involved in developing CAR-T cell drugs, preparation of cells and regenerative medicine and also offers technical services. The company is headquartered in Dongguan, Guangdong, China.
For a complete picture of XKDCT-080’s drug-specific PTSR and LoA scores, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#XKDCT080 #Guangdong #Xiankangda #Biotechnology #Colorectal #Cancer #Likelihood #Approval
